185 related articles for article (PubMed ID: 31227055)
21. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography (PET) radiotracers for prostate cancer imaging.
Walker SM; Lim I; Lindenberg L; Mena E; Choyke PL; Turkbey B
Abdom Radiol (NY); 2020 Jul; 45(7):2165-2175. PubMed ID: 32047993
[TBL] [Abstract][Full Text] [Related]
23. Novel imaging in advanced prostate cancer.
Goldberg H; Hamilton RJ
Curr Opin Support Palliat Care; 2017 Sep; 11(3):238-246. PubMed ID: 28590314
[TBL] [Abstract][Full Text] [Related]
24. Clinical PET Imaging in Prostate Cancer.
Wallitt KL; Khan SR; Dubash S; Tam HH; Khan S; Barwick TD
Radiographics; 2017; 37(5):1512-1536. PubMed ID: 28800286
[TBL] [Abstract][Full Text] [Related]
25. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
26. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
27. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer PET tracers: essentials for the urologist.
Fraum TJ; Ludwig DR; Kim EH; Schroeder P; Hope TA; Ippolito JE
Can J Urol; 2018 Aug; 25(4):9371-9383. PubMed ID: 30125515
[TBL] [Abstract][Full Text] [Related]
29. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Siva S; Udovicich C; Tran B; Zargar H; Murphy DG; Hofman MS
Nat Rev Urol; 2020 Feb; 17(2):107-118. PubMed ID: 31937920
[TBL] [Abstract][Full Text] [Related]
30. Where to next prostate-specific membrane antigen PET imaging frontiers?
Donswijk ML; Morigi JJ; Little A; Vogel WV; van Leeuwen PJ
Curr Opin Urol; 2020 Sep; 30(5):672-678. PubMed ID: 32701718
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
32. PET imaging of recurrent and metastatic prostate cancer with novel tracers.
Mertan FV; Lindenberg L; Choyke PL; Turkbey B
Future Oncol; 2016 Nov; 12(21):2463-2477. PubMed ID: 27527923
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
34. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Hofman MS; Iravani A; Nzenza T; Murphy DG
Urol Clin North Am; 2018 Aug; 45(3):503-524. PubMed ID: 30031469
[TBL] [Abstract][Full Text] [Related]
35. Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.
Rowe SP; Gorin MA; Pomper MG
Annu Rev Med; 2019 Jan; 70():461-477. PubMed ID: 30691373
[TBL] [Abstract][Full Text] [Related]
36. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
37. The use of PET/CT in prostate cancer.
Li R; Ravizzini GC; Gorin MA; Maurer T; Eiber M; Cooperberg MR; Alemozzaffar M; Tollefson MK; Delacroix SE; Chapin BF
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):4-21. PubMed ID: 29230009
[TBL] [Abstract][Full Text] [Related]
38. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
39. Novel Imaging in Detection of Metastatic Prostate Cancer.
Smith CP; Laucis A; Harmon S; Mena E; Lindenberg L; Choyke PL; Turkbey B
Curr Oncol Rep; 2019 Mar; 21(4):31. PubMed ID: 30834999
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
